Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2023 08:00 ET | Source: Morphic Therapeutic

Morphic to Present at November Investor Conferences

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
August 29, 2023 08:00 ET | Source: Morphic Therapeutic

Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
June 06, 2023 16:05 ET | Source: Morphic Therapeutic

Morphic to Present at the Jefferies Global Healthcare Conference

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
May 05, 2023 10:30 ET | Source: Morphic Therapeutic

Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...
May 03, 2023 00:13 ET | Source: Morphic Therapeutic

Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious...
April 24, 2023 16:01 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023

WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
January 05, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
September 03, 2020 16:30 ET | Source: Morphic Therapeutic

Morphic Announces Participation in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
August 25, 2020 06:30 ET | Source: Morphic Therapeutic

Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases

AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
August 10, 2020 07:00 ET | Source: Morphic Therapeutic

Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results

Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...

Next Page keyboard_arrow_right